These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30969990)

  • 1. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
    Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
    PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
    Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
    Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
    Fujiki H; Sueoka E; Watanabe T; Suganuma M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
    Eicher C; Dewerth A; Thomale J; Ellerkamp V; Hildenbrand S; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Br J Cancer; 2013 Feb; 108(2):334-41. PubMed ID: 23257893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720-induced enhancement of autophagy protects cells from FTY720 cytotoxicity in colorectal cancer.
    Li J; Wang SW; Zhang DS; Sun Y; Zhu CY; Fei Q; Hu J; Zhang C; Sun YM
    Oncol Rep; 2016 May; 35(5):2833-42. PubMed ID: 26985637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.
    Bownes LV; Julson JR; Quinn CH; Hutchins SC; Erwin MH; Markert HR; Stewart JE; Mroczek-Musulman E; Aye J; Yoon KJ; Ohlmeyer M; Beierle EA
    J Pediatr Surg; 2023 Jun; 58(6):1145-1154. PubMed ID: 36907775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
    Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
    Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
    Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.
    Garner EF; Williams AP; Stafman LL; Aye JM; Mroczek-Musulman E; Moore BP; Stewart JE; Friedman GK; Beierle EA
    Sci Rep; 2018 May; 8(1):6913. PubMed ID: 29720672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
    Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
    Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients.
    Wagner F; Henningsen B; Lederer C; Eichenmüller M; Gödeke J; Müller-Höcker J; von Schweinitz D; Kappler R
    Eur J Cancer; 2012 Oct; 48(15):2442-50. PubMed ID: 22285179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
    Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
    J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.
    Szymiczek A; Pastorino S; Larson D; Tanji M; Pellegrini L; Xue J; Li S; Giorgi C; Pinton P; Takinishi Y; Pass HI; Furuya H; Gaudino G; Napolitano A; Carbone M; Yang H
    J Transl Med; 2017 Mar; 15(1):58. PubMed ID: 28298211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.